TICKERNERD
Menu
BVSBVSHealthcare · Medical Devices

BVS Stock Forecast: Bioventus, Inc. Price Predictions for 2026-2027

Last close, 21 Sept 2026
$13
+3.10% on the day

The 5 Wall Street analysts covering Bioventus, Inc. hold a median 12-month price target of $18 — +35.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 19 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$881.8M
Ticker Nerd rank
98 / 100
Median analyst target
$18
Analysts covering
5
Revenue$153.2M+3.8% y/y
Operating income$18.7M
Net income$36.2M
Free cash flow$18.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.1%
1M
−7.4%
YTD
+78.9%
1Y
+92.1%
From 52W high
−12.8%
From 52W low
+104.5%
$7
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BVS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bioventus, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
98 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
97
Value
90
Momentum
86
Issuance
84
Accruals
82
Growth
78
Volatility
52
Revisions
52
Size
44

Quality (97): The business earns solid, repeatable profits on what it owns.

Revisions (52): Analysts have, on balance, been cutting their forecasts.

Size (44): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BVS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BVS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Oct 25Jan 26Apr 26Jul 26BVSHigh $19Median $18Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $15Median $18High $19

The green dot is the last close — the median target sits +35.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026Canaccord GenuityMaintainsBuy$15 → $19
17 Aug 2026Cantor FitzgeraldReiteratesOverweight$15
30 June 2026Barrington ResearchMaintainsOutperform—
30 June 2026Barrington ResearchMaintainsOutperform$14
16 June 2026Canaccord GenuityMaintainsBuy—
22 May 2026Barrington ResearchMaintainsOutperform—
6 Mar 2026Barrington ResearchMaintainsOutperform—
6 Mar 2026Craig-HallumMaintainsBuy—
9 Feb 2026Barrington ResearchInitiatesOutperform—
7 July 2025Cantor FitzgeraldInitiatesOverweight—
17 Mar 2025Canaccord GenuityMaintainsBuy—
17 Dec 2024JP MorganUpgradeNeutral—
6 Nov 2024Canaccord GenuityMaintainsBuy—
27 Sept 2024Craig-HallumMaintainsBuy—
13 Aug 2024Canaccord GenuityMaintainsBuy—
7 Aug 2024Craig-HallumMaintainsBuy—
8 May 2024Canaccord GenuityMaintainsBuy—
13 Mar 2024Craig-HallumMaintainsBuy—
7 Dec 2023Canaccord GenuityUpgradeBuy—
3 Apr 2023Craig-HallumMaintainsHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BVS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BVS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 21 Sept 2026, Bioventus, Inc. returned +92.1% against +15.7% for the S&P 500, dividends included.

BVS vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200220Oct 25Jan 26Apr 26Jul 26BVSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BVS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.3%
Analysts raising
0
Analysts cutting
1
Fundamentals

Bioventus, Inc. (BVS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
16.6×

Cheaper than 43% of US stocks

Price / sales
1.5×

Cheaper than 59% of US stocks

Price / book
3.9×

Cheaper than 26% of US stocks

EV / EBITDA
14.5×

Cheaper than 23% of US stocks

Growth & margins
Revenue growth (YoY)
3.8%

Higher than 36% of US stocks

Earnings growth (YoY)
348.3%

Higher than 93% of US stocks

Gross margin
69.0%

Higher than 82% of US stocks

Operating margin
12.2%

Higher than 68% of US stocks

Net margin
9.4%

Higher than 68% of US stocks

Returns & dividend
Return on equity
25.7%

Higher than 85% of US stocks

Return on assets
5.5%

Higher than 79% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Bioventus, Inc. (BVS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Bioventus, Inc. has a market value of $881.8M and an enterprise value of $1.2B.

  • Revenue in the twelve months to 30 June 2026: $581.8M. The latest quarter grew 3.8% year on year.

  • Net income over the same four quarters: $61.5M, a 10.6% net margin.

  • Diluted earnings per share, trailing twelve months: $0.77.

  • Free cash flow in the twelve months to 30 June 2026: $94.3M.

  • Shares outstanding: 68.2M.

  • Trailing P/E: 16.6×; forward P/E: 14.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Bioventus, Inc. employs 950 people — $612K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

BVS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
BVSBioventus, Inc.$881.8M
98
IRMDIRadimed Corp.$1.1B
89
PRCTPROCEPT BioRobotics Corp.$1.1B
38
LMRILumexa Imaging Holdings, Inc.$1.0B
1
ENOVEnovis Corp.$1.0B
80
AORTArtivion, Inc.$1.1B
41
BBNXBeta Bionics, Inc.$1.2B
40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bioventus, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BVS news & analysis

Bioventus: Cash Flow Anchors The Bull Case Beyond A Potential Sale

Seeking Alpha · 21 Sept 2026positive

Bioventus is positioned on a bullish outlook based on cash generated from established products, which it uses to reduce debt and fund commercial expansion. The company benefits from improved financing flexibility, including a term loan maturity extended to 2030 and a 75 basis points interest margin reduction, with execution focused on sustained cash flows, product adoption, and repeat physician usage.

Why it matters — A BVS watcher would care because the company's deleveraging progress and improved financing terms support its commercial growth plans and the bull case beyond a potential sale.

Are Medical Stocks Lagging Bioventus (BVS) This Year?

Zacks Investment Research · 24 Aug 2026neutral

A Zacks Investment Research article examines how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year, questioning whether medical stocks are lagging Bioventus. The piece compares the two companies' year-to-date performance against their sector.

Why it matters — BVS watchers would care because the article places Bioventus's year-to-date performance in context relative to both a peer company and its broader sector.

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike

Zacks Investment Research · 20 Aug 2026positive

Zacks Investment Research published an article suggesting healthcare stocks, including Bioventus (BVS), as portfolio options amid expected Federal Reserve rate hikes and elevated inflation, which could keep markets volatile.

Why it matters — The article highlights BVS as a healthcare stock that investors may consider as a defensive option during periods of market volatility tied to rate hikes.

Is Bioventus (BVS) Stock Undervalued Right Now?

Zacks Investment Research · 7 Aug 2026neutral

Zacks Investment Research published an article questioning whether Bioventus (BVS) stock is undervalued, focusing on its Zacks Rank system that emphasizes earnings estimates and revisions, while also monitoring value, growth, and momentum trends.

Why it matters — BVS watchers would care because the analysis touches on whether the stock may be undervalued based on earnings trends, a key input for investment decisions.

Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

Seeking Alpha published the transcript of Bioventus, Inc.'s Q2 2026 earnings call. The document contains the company's earnings call discussion for that period.

Why it matters — The transcript gives BVS watchers direct access to management's commentary on the quarter's performance and outlook.

FAQ

Frequently asked questions about BVS stock

What is the BVS stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Bioventus, Inc. have a median 12-month price target of $18, with estimates ranging from $15 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BVS stock a buy right now?

Of the 5 analysts covering Bioventus, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bioventus, Inc. 98 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BVS?

As at 19 Sept 2026, Bioventus, Inc. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (97 of 100).

Will BVS stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +35.2% from the last close, and Ticker Nerd's factor model ranks Bioventus, Inc. 98 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BVS stock forecast for 2030?

No analyst covering Bioventus, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BVS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $19 over the next 12 months.

How has BVS stock performed over the past year?

Bioventus, Inc. returned +92.1% over the 12 months to 21 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bioventus, Inc. do?

Bioventus Inc. Class A Common Stock represents Bioventus Inc., a medical technology company focused on developing and commercializing products for musculoskeletal care and active healing.

What is the latest news on BVS?

The most recent item we track (Seeking Alpha, 21 Sept 2026): "Bioventus: Cash Flow Anchors The Bull Case Beyond A Potential Sale". Bioventus is positioned on a bullish outlook based on cash generated from established products, which it uses to reduce debt and fund commercial expansion. The company benefits from improved financing flexibility, including a term loan maturity extended to 2030 and a 75 basis points interest margin reduction, with execution focused on sustained cash flows, product adoption, and repeat physician usage.

Company

About Bioventus, Inc.

Bioventus Inc. Class A Common Stock represents Bioventus Inc., a medical technology company focused on developing and commercializing products for musculoskeletal care and active healing. Bioventus serves patients and healthcare providers with orthobiologic and restorative solutions designed to support bone healing, pain treatment, and recovery from a range of orthopedic conditions. Its current business is organized around active healing therapies, surgical solutions, and related products used in both U.S. and international markets. The company’s portfolio includes therapies such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture-healing technologies. Bioventus operates as a specialized healthcare company within the broader medical device sector, with offerings aimed at non-surgical and surgical treatment settings.

CEO Mr. Robert E. Claypoole · 950 employees · United States · https://www.bioventus.com